TORONTO - Ion Beam Applications (IBA) has developed and is completing tests for a new modular, multipurpose automatic synthesizer.
The synthesizer allows for the preparation of various PET radiopharmaceuticals and shows potential for use in developing new molecular probes, according to the Louvain-la-Neuve, Belgium-based firm.
In related news, the vendor's Sterling, VA-based Eastern Isotopes subsidiary has entered into a scientific collaboration with Molecular Insight Pharmaceuticals of Cambridge, MA. The collaboration will focus on Molecular Insight's proprietary Ultratrace solid-phase radiolabelling technology and the iodine-124 (I-124) commercial production capabilities of Eastern Isotopes.
The firms will be working on furthering the development of I-124 meta-iodobenzylguanidine (MIBG) for the diagnosis and treatment planning of neuroendocrine malignancies such as neuroblastoma, pheochromocytoma, and carcinoid, Eastern Isotopes said.
IBA also announced that Eastern Isotopes has agreed to support a Society of Nuclear Medicine (SNM) educational grant for an undisclosed amount. The grant will fund a new SNM Web-based educational PET program for physicians, pharmacists, scientists, and technologists. The grant will also support a monthly PET teaching case study available on the SNM Web site. Both programs are expected to begin this fall.
By AuntMinnie.com staff writers
June 20, 2005
Related Reading
IBA adds radiopharmacies, January 21, 2005
IBA sells cyclotron to University of Florida, January 10, 2005
Eastern Isotopes to launch dementia PET training program, December 16, 2004
Eastern Isotopes launches California pharmacy, July 15, 2004
Eastern Isotopes, VCU collaborate, June 22, 2004
Copyright © 2005 AuntMinnie.com
